Aurobindo Pharma is reportedly in discussion with Shreya Life Sciences for a deal to buy the latter’s Russian business. The potential deal is valued between $80 million to $100 million.
The company has given a term sheet and the deal now depends on the final valuation. However, this could be a complex process as the Mumbai-based Shreya Life Sciences may not be keen on selling the entire business and prefer retaining some share.
Shreya Life Sciences was established in 2001 and deals with a wide variety of pharmaceutical products. The company runs operations all over the world and had started its Russian operations just a year after its birth.
Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1880.40 |
| Dr. Reddys Lab | 1287.25 |
| Cipla | 1308.00 |
| Zydus Lifesciences | 954.10 |
| Lupin | 2266.85 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: